Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for BioCorRx (BICX) over the last 15 years, with Q3 2025 value amounting to 306.05%.

  • BioCorRx's EBITDA Margin changed N/A to 306.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 569.42%, marking a year-over-year increase of 174541100.0%. This contributed to the annual value of 66412.77% for FY2024, which is 621932000.0% down from last year.
  • Per BioCorRx's latest filing, its EBITDA Margin stood at 306.05% for Q3 2025.
  • BioCorRx's 5-year EBITDA Margin high stood at 306.05% for Q3 2025, and its period low was 33694.26% during Q2 2024.
  • For the 5-year period, BioCorRx's EBITDA Margin averaged around 8788.56%, with its median value being 5449.39% (2022).
  • Per our database at Business Quant, BioCorRx's EBITDA Margin plummeted by -289044500bps in 2024 and then soared by 329033100bps in 2025.
  • Quarter analysis of 5 years shows BioCorRx's EBITDA Margin stood at 9742.67% in 2021, then skyrocketed by 85bps to 1422.86% in 2022, then tumbled by -203bps to 4310.34% in 2023, then plummeted by -682bps to 33694.26% in 2024, then surged by 99bps to 306.05% in 2025.
  • Its EBITDA Margin was 306.05% in Q3 2025, compared to 790.96% in Q2 2025 and 692.5% in Q1 2025.